Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock? – Merrimack Pharmaceuticals Inc (MACK), TESARO Inc (TSRO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has seen an increase in hedge fund interest in recent months.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)

To most stock holders, hedge funds are perceived as worthless, old financial vehicles of years past. While there are more than 8000 funds in operation at the moment, we hone in on the upper echelon of this club, close to 450 funds. It is estimated that this group has its hands on most of the hedge fund industry’s total capital, and by watching their best equity investments, we have spotted a few investment strategies that have historically outpaced the broader indices. Our small-cap hedge fund strategy outpaced the S&P 500 index by 18 percentage points annually for a decade in our back tests, and since we’ve began to sharing our picks with our subscribers at the end of August 2012, we have outperformed the S&P 500 index by 24 percentage points in 7 months (see all of our picks from August).

Equally as beneficial, bullish insider trading activity is another way to parse down the stock market universe. There are lots of reasons for an upper level exec to cut shares of his or her company, but only one, very simple reason why they would behave bullishly. Various academic studies have demonstrated the valuable potential of this method if investors know where to look (learn more here).

Consequently, let’s take a gander at the latest action encompassing Halozyme Therapeutics, Inc. (NASDAQ:HALO).

How are hedge funds trading Halozyme Therapeutics, Inc. (NASDAQ:HALO)?

In preparation for this year, a total of 12 of the hedge funds we track were bullish in this stock, a change of 9% from one quarter earlier. With the smart money’s capital changing hands, there exists an “upper tier” of key hedge fund managers who were increasing their stakes meaningfully.

According to our comprehensive database, QVT Financial, managed by Daniel Gold, holds the largest position in Halozyme Therapeutics, Inc. (NASDAQ:HALO). QVT Financial has a $25.4 million position in the stock, comprising 1.7% of its 13F portfolio. Sitting at the No. 2 spot is Baker Bros. Advisors, managed by Julian Baker and Felix Baker, which held a $11.9 million position; 0.3% of its 13F portfolio is allocated to the stock. Other hedgies with similar optimism include Israel Englander’s Millennium Management, Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management and John A. Levin’s Levin Capital Strategies.

As industrywide interest jumped, key money managers have been driving this bullishness. Sectoral Asset Management, managed by JΘr⌠me Pfund and Michael Sj÷str÷m, assembled the biggest position in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Sectoral Asset Management had 5.8 million invested in the company at the end of the quarter. Jim Simons’s Renaissance Technologies also made a $1.1 million investment in the stock during the quarter. The following funds were also among the new HALO investors: Mike Vranos’s Ellington, D. E. Shaw’s D E Shaw, and Steven Cohen’s SAC Capital Advisors.

What have insiders been doing with Halozyme Therapeutics, Inc. (NASDAQ:HALO)?

Insider buying is particularly usable when the primary stock in question has seen transactions within the past 180 days. Over the last six-month time frame, Halozyme Therapeutics, Inc. (NASDAQ:HALO) has experienced 2 unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to Halozyme Therapeutics, Inc. (NASDAQ:HALO). These stocks are InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), TESARO Inc (NASDAQ:TSRO), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and EXACT Sciences Corporation (NASDAQ:EXAS). This group of stocks are the members of the biotechnology industry and their market caps match HALO’s market cap.

Company Name # of Hedge Funds # of Insiders Buying # of Insiders Selling
InterMune Inc (NASDAQ:ITMN) 14 0 0
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) 7 3 1
TESARO Inc (NASDAQ:TSRO) 2 1 0
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 12 0 4
EXACT Sciences Corporation (NASDAQ:EXAS) 11 2 0

With the returns shown by the aforementioned strategies, everyday investors should always pay attention to hedge fund and insider trading activity, and Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders fit into this picture quite nicely.

Click here to learn why you should track hedge funds

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

The 10 Biggest Tax Havens in the World to Stash Your Money

The 15 Most Murderous Countries in the World

10 Largest Colleges in the World: Bigger Isn’t Always Better

Comedians in Cars Getting Coffee: The 6 Comedians Seinfeld Needs to Interview

Easy Money: The 10 Most Successful Investors in the World Today

The 10 Most Deadly Diseases in the World Today

The 5 Most Expensive Luxury Motorhomes in the World

20 Largest Stock Exchanges in the World

6 Richest Painters In The World 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!